At the cellular level, EGFR inhibitors result in cell cycle arrest at the G1 phase (Wu et al, 1995; Busse et al, 2000), decrease tumour neovascularisation by downregulating expression of angiogenic mediators such as vascular endothelial growth factor (VEGF) (Perrotte et al, 1999; Ciardiello et al, 2001a), and promote apoptosis (Moyer et al, 1997; Liu et al, 2000). The gene discussed is EGFR; the disease is neoplasm.